Transforming cancer outcomes in England: earlier and faster diagnoses, pathways to success, and empowering alliances

Christopher J Harrison¹
Roger G Spencer²
David C Shackley³

¹University of Manchester Division of Cancer Sciences, The Christie NHS Foundation Trust, Manchester, UK;
²Chief Executive's Office, The Christie NHS Foundation Trust, Manchester, UK;
³University of Manchester Division of Cancer Sciences, Greater Manchester Cancer, Manchester, UK

Abstract: Cancer outcomes and patient experience in England have never been better but survival remains worse than in comparable countries. Differences in stage at diagnosis and, to a lesser extent, access to optimal treatments are likely to be the most important factors. The national cancer plan emphasizes earlier and faster diagnosis and the creation of cancer alliances providing strategic leadership and coordination. Earlier diagnosis is being promoted by national awareness campaigns designed to overcome fatalism and perceived barriers to consulting a general practitioner as well as improvements to existing screening programs and the introduction of more targeted screening such as Lung Health Checks. These are supported by local social marketing campaigns in which trained volunteers support and advise others about cancer and cancer care. The epidemiology of symptoms in general practice provides an organizing framework for cancer diagnostic pathways. Alliances are implementing a broader model of cancer diagnostic clinics at a larger scale taking into account the different needs of patients with 1) obvious alert symptoms, 2) low risk but not no risk symptoms, and 3) serious but not specific symptoms. Faster diagnosis is being promoted by the introduction of a Faster Diagnosis Standard requiring patients are given a diagnosis of cancer or have it ruled out within 28 days of referral. The three cancer alliances forming the National Cancer Vanguard together with NHS England are publishing clinically led evidence-based Timed Diagnostic Pathways which show how the drastic changes needed can be achieved. Cancer alliances have been successful in developing clinical cancer pathways which need support by improved commissioning and regulatory approaches which align clinical pathways with financial and performance ratings. Clinical leadership has been essential but further focus is needed on making sure that performance and regulatory approaches give proper attention and encouragement to earlier and faster diagnosis.

Keywords: cancer, pathways, outcomes, vanguard, diagnosis, rapid

The NHS landscape
Since the first cancer plan for England was published in 2000,¹ there have been remarkable improvements in cancer care. More people than ever before now survive cancer and the number of people alive in the UK having had a cancer diagnosis is rapidly approaching 3 million and is projected to pass 4 million by 2030.² More attention is now paid to prevention and early detection of cancer, and treatments have become less toxic and more personalized.³ More patients than ever before report a positive experience of their cancer care.⁴ The UK has some of the world's leading cancer research groups and programs.⁵ Despite this, there remain unacceptable geographical differences in survival rates within England⁶ and reported cancer outcomes in England.
as a whole remain below those in comparable countries. Cancer Research UK (CRUK) reports that the most likely reason for this differential lower survival is the difference in stage at diagnosis.

Reforms to the NHS introduced by the Health and Social Care Act (2012) devolved greater power and budgetary control to local clinical commissioning groups (CCGs) operating with a regulated provider system. Private providers were to be able to compete with centrally accountable NHS Trusts and NHS Foundation Trusts with greater operational and financial freedoms and local accountability. However, the loss of regional coordination mechanisms led to widespread confusion with the loss of many of the formal cancer networks which had previously overseen cancer care and patient pathways leading to disjointed planning and variation in access to cancer care. Dissatisfaction was such that in 2014 NHS England published a Five Year Forward View which sought to introduce new models of care, provider–provider and provider–commissioner collaborations aimed at generating savings and efficiencies as well as improving clinical outcomes. Competition was to be replaced with strategic cooperation through system wide Sustainability and Transformation Programmes albeit that these were introduced without new legislation and therefore were without a statutory basis.

The Five Year Forward View identified cancer as a national clinical priority and in 2015 the government accepted the advice from an independent national cancer task force that much of the difference in cancer survival rates between England and comparable countries is due to later presentation to medical services. The UK has a less favorable stage distribution than comparable countries. For example, 20.3% of non-small-cell lung cancer is diagnosed at an early stage (I or II) in England compared with 25% in Canada. The taskforce also pointed out that onward referral to specialist care in countries with a “gatekeeping role” for primary care is later and 1 year survival lower than in those without such a filter function. General practitioners (GPs) in England see up to a quarter of cancer patients three or more times before a hospital referral and access to diagnostic tests by English GPs is less than half of that found in other countries. In addition, English GPs have poorer access to specialized advice to guide investigation or referral. Why is earlier detection of cancer beneficial?

Treatment when cancer is diagnosed earlier is generally

- More effective – for example, in colorectal cancer 90% of people with the earliest stage live 10 years or more compared with 5% for the most advanced disease.
- Shorter, less complex and with less marked side effects – typically with enhanced experience of care and more positive subsequent quality of life.
- Less expensive – for example, in colorectal cancer early stage treatment typically costs £3,400 and £12,500 for later stage.

Public awareness and consultation behavior

Forbes et al studied whether people from countries with lower cancer survival (UK and Denmark) were less aware of cancer symptoms or held more negative beliefs about cancer than those from countries where survival is higher (Australia, Canada, and Sweden). UK patients were less likely to know that cancer risk increases with age and had the highest rates of perceived barriers to seeking medical advice on symptoms. This was most clearly expressed in terms of worrying about wasting the doctor’s time which was cited as a cause of delay by 34% of the UK subjects compared with 21%, 14%, 12%, 11%, and 9% in Canada, Australia, Denmark, Norway and Sweden, respectively. A study by CRUK showed that although recognition of cancer alert symptoms was high, over a third of patients agreed or strongly agreed that the following things might put them off going to the doctors: “I find it difficult to get
an appointment at a convenient time”; “I find it difficult to get an appointment with a particular doctor”; “I don’t like having to talk to the GP receptionist about my symptoms”;
and “I don’t want to be seen as someone who makes a fuss”.22

Since 2010, Be Clear on Cancer23 (BCOC) has become a well-established program, working to improve cancer outcomes and reduce health inequalities within England. The program presents cancer messages in a credible and acceptable way for specific target population groups. Extensive clinical and public testing and piloting is undertaken in developing campaigns in order to ensure that campaigns prompt appropriate action rather than merely raising awareness of symptoms.24

BCOC Oesophago-Gastric Cancer25 campaigns in 2014 and 2015 successfully raised awareness of two important symptoms of esophago-gastric cancer (heartburn and difficulty swallowing) and prompted people to see their GP. There was a corresponding increase in the number of referrals for suspected upper gastrointestinal (upper GI) cancer and an increase in the number of cases of esophageal cancer diagnosed during the campaign period. Similar findings have been reported in other BCOC campaigns such as the national breathlessness campaign in 201726 and the national breast cancer campaign in 2018 which targeted women over 70 years of age.27

In a prostate cancer regional pilot campaign, the key message was targeted at black men who have a one in four life-time risk of prostate cancer. Although a very small pilot localized to six London boroughs over a 4-week period, the program did show that awareness could be raised in the target group and there was a small effect on stage at diagnosis although not on any other clinical outcome indicator.28

Local cancer alliance–led initiatives can complement national campaigns. The Cancer Champion29 (Greater Manchester) and the Be Cancer Safe campaign30 (Bassetlaw and North Derbyshire) exemplify social movements in which trained members of the public spread prevention and early detection messages, support people, and prompt action throughout local communities. In Greater Manchester, the aim is to train up to 20,000 local volunteers by 2020, and in Bassetlaw and North Derbyshire, 1,840 champions had been recruited within 2 months of the campaign launch.29,30

Cancer treatments are increasingly effective, precise and personal, and, with some exceptions, considerably less toxic.3 The experience is that these changes may not yet have permeated into the collective public understanding of cancer in England, and this may be one factor leading to the continued observed reticence to consult GPs because of fatalism about the condition and fear of treatment. Approaches such as BCOC in England and regional social marketing campaigns led by cancer alliances are addressing these more general underlying perceptions and barriers to consultation.

**Case-finding and screening of higher risk groups**

There has been much debate in England about introducing more selective screening approaches, targeted at population sub-groups at higher risk. These complement the national population-based cancer screening programs (breast,31 colorectal,32 and cervical cancer33 overseen by the National Screening Committee34 and which currently detect around 5% of all cancer cases in England, including around 30% of breast cancers and 10% of bowel cancers).35 With new technological approaches, there is potential to diagnose more asymptomatic cancers (and by implication, early stage) with new screening techniques. Such programs must be piloted and thoroughly evaluated before broader introduction.

Currently, there is no population screening program for lung cancer. However, the 20% mortality reduction for those screened with low-dose CT, compared with chest X-ray in the US National Lung Screening Study led to lung screening being recommended for ex-smokers aged 55–80 years in the USA and a series of small-scale pilot studies being introduced across England.36

The Manchester Lung Health Check Study was a community-based pilot of targeted, low-dose computerized tomography (LDCT) screening for lung cancer. The population covered was those who had ever smoked, aged 55–74 years, and living in some of the most economically deprived areas of Manchester. People meeting the criteria were invited to undergo a lung health check which included immediate access to LDCT for those with high risk of lung cancer. The check was undertaken in mobile facilities located next to local shopping centers. Of 1,384 patients screened, 3% had lung cancer of which 80% were at an early stage and 65% of which underwent surgical resection.37,38

The study concluded that “Taking lung cancer screening into communities, with a Lung Health Check approach, is effective and engages populations in deprived areas”. Similar initiatives in Liverpool, Nottingham, and London had comparable results.37 NHS England’s Clinical Expert Group for Lung Cancer has developed a service specification setting out the objectives, service requirements, and standards required for these services. A national implementation program starting with areas in England with the lowest survival rates for lung cancer is in progress. The recently released positive
results of the Nelson trial can only support this approach and act as a prompt to consideration of a wider program.\textsuperscript{40}

**Innovation and research in earlier diagnosis**

Innovation in the area of earlier cancer diagnosis has noticeably accelerated in recent years. Developments in the understanding of the human genome and the basic causes of cancer have enabled us to start to identify the earliest preclinical signs of cancer such as through detection in the blood of circulating tumor cells or DNA. Current advances offer huge opportunities for identifying new markers for risk, tumor development, treatment effectiveness, and relapse and over the next 5 years seem set to revolutionize how we diagnose and classify cancer.

As part of this effort, the nationally funded Biomedical Research Center\textsuperscript{41} at Manchester University has a major work program dedicated to cancer prevention and early detection. Work streams focus on risk stratification, imaging and molecular biomarkers, obesity-related cancers, and new service models such as the lung health check approach already described. The emphasis in Manchester is to “pivot” toward research of prevention and earlier detection of cancer where it is felt there is more population benefit in the long term.\textsuperscript{41}

CRUK has identified the following areas of focus for research into the early detection of cancer:\textsuperscript{41}

- Biological research underpinning early detection and biomarker discovery/validation
- Human-based early detection discovery research
- Population risk-stratification for early detection
- Biomedical and health informatics, and systems biology for early detection
- Development and utilization of preclinical early detection model systems
- Novel early detection technology development
- Translational/clinical early detection research

In addition, CRUK is creating an elite alliance of world-leading UK and US centers of excellence in early detection research to catalyze a step-change in progress in this field. A recent call for applications is for UK institutions to become member centers of this alliance with up to £10 million available to support two to three UK centers over 5 years.\textsuperscript{42}

Earlier detection of cancer was one of the key aspects of the 2015 independent taskforce report\textsuperscript{16} and NHSE has already signaled in its consultation on the new long-term plan for the NHS that this will remain an important element of the cancer component.\textsuperscript{43}

**Primary care assessment and referral**

Primary care assessment of possible cancer symptoms can be complex with symptoms often being similar to benign self-limiting conditions. The 2017 National Cancer Patient Experience Survey shows that just under a quarter of patients subsequently diagnosed with cancer saw their GP three times or more before referral for tests, after initially presenting in primary care. Eight percent of patients saw their GP five or more times before referral.\textsuperscript{4}

In Denmark, work\textsuperscript{44} drew on the epidemiology of cancer symptoms to characterize the first symptomatic presentation of cancer patients in general practice into three groups each requiring a different type of response from the GP. About 50% of patients had “obvious” alarm symptoms requiring urgent referral, 30% had normal “common” vague symptoms requiring a specific test to exclude the possibility or confirm cancer, and 20% had symptoms that are “difficult” to assess because they are serious but not specific for cancer and that require more careful specialist assessment and investigation.

This classification is based on Danish data, but its applicability to England is consistent with the finding that 50% of cancer patients in the UK did not have symptoms that would have triggered an urgent referral under the National Institute for Health and Care Excellence guidelines recorded in their notes.\textsuperscript{35}

International studies suggest that English primary care practitioners have a low propensity to refer or investigate symptoms for cancer at first presentation, have a low level of direct access to tests such as imaging for cancer, and have a low level of rapid access to specialist advice in problematic cases. Willingness to investigate at first presentation correlates with 1- and 5-year survival across a range of types of cancer.\textsuperscript{46}

Countries such as England with a strong gatekeeper role for primary care have been shown to have the lowest cancer survival rates.\textsuperscript{47} This finding has underpinned policy responses in both England and Denmark which seek to support GPs rather than replace them with alternative mechanisms for cancer diagnosis.

**Patients with obvious alert symptoms for cancer**

The NHS in England has instituted rapid access referral pathways for specific “obvious” cancer alarm symptoms. Symptoms or groups of symptoms which indicate urgent referral to be seen within 2 weeks are defined by guidelines issued by NICE, based on the assessment of the positive predictive values (PPVs) of different symptom combinations.\textsuperscript{48}
Updated guidance published in 2015 lowered the threshold for referral in the guidance from a PPV of about 11% to 3%. As pointed out at the time of their introduction, this would mean that the number of referrals would dramatically increase so that rather than nine urgent referrals for one case of cancer, there would be 33 urgent referrals for one confirmed case. Indeed large increases have been recorded with the number of urgent referrals across England with suspected cancer increasing from 1.6 million in 2014/2015 to 2.0 million in 2017/2018. In some pathways, the growth in referrals for urgent assessment has been very marked: in the Greater Manchester Alliance area (catchment 3 million), over the 3 years 2015–2017, there was a 40% increase in suspected colorectal cancer referrals.

The NICE guidelines are clear and evidence based while leaving scope for clinical “gut feeling”. They are however complex and may be difficult to recall and apply in the middle of a consultation. In addition to locally based referral forms and systems, a variety of support packages to aid GP decision-making have been introduced. For example, Gateway C is an online educational package originally developed by the National Cancer Vanguard (NCV) to assist GPs in understanding and applying the NG12 criteria and other aspects of cancer care. The online courses are interactive and are developed by GPs and other specialists to ensure insights from those regularly dealing with specific cancers. Originally piloted in Greater Manchester, the Gateway C approach is now available to GPs and cancer alliances across England. Gateway C is a training module for primary care as opposed to real-time decision support (RTDS). Increasingly, RTDS is being incorporated into primary care information technology systems which should also support primary care professionals during the consultation.

**Patients with serious but non-specific symptoms**

For “common” vague symptoms that have a low risk of cancer, but the diagnosis cannot be completely excluded without investigation, the English independent task force recommended in 2015 that “NHS England should mandate that GPs have direct access to key investigative tests for suspected cancer – blood tests, chest x-ray, ultrasound, MRI, CT and endoscopy – by the end of 2015”. This reiterates previous initiatives going back to the 2000 Cancer Plan for England which explicitly referred to increases in diagnostic capacity and the availability of direct access to tests such as endoscopy by GPs. The NICE guidance on urgent referrals also contains recommendations on direct access use of tests by GPs.

A survey and analysis of the national diagnostic imaging data set suggests that access to diagnostic tests has been increasing across England although not at the rate required to implement the national strategy in full. There remain variations in access and priority given to improvements in cancer diagnostic facilities between CCGs. For example, the number of imaging tests increased by 4.6 million from 2012/2013 to 2015/2016, and while in the same period some CCGs have seen a 6.2% increase in CT scans, others have seen a reduction of 2.1%.

** Patients with serious but non-specific symptoms**  

The % of cancer patients falling into the category of “difficult”, consult GPs for the first time with non-specific or vague symptoms which while not suggestive of a specific type of cancer do indicate the probability of a serious underlying condition. These patients pose a dilemma for GPs because they do not easily fit the criteria of the NG12 pathways and the clinical picture is more complex than the requirement for a single one-off test. Nevertheless, a variety of sources suggest that the likelihood of these patients having a cancer diagnosis is up to 16% with the probability of some form of serious non-cancer condition being up to a third.

In England, a series of pilots of cancer pathway innovations have been undertaken through the Accelerate Coordinate Evaluate Programme (ACE). The second wave (ACE2) has concentrated on the concept of multidisciplinary cancer diagnostic clinics (MDCs) and their applicability in the NHS.

The ten ACE2 sites are testing pathways for patients with non-specific symptoms that could be indicative of cancer, but who do not currently meet the criteria for urgent referral. Current evidence suggests that MDCs will be an effective way to diagnose cancer within this patient group. The mid-point evaluation of the ACE2 reports that of patients referred to the MDCs the most common symptom was weight loss (62%), followed by nausea and appetite loss (28%), abdominal pain (25%), and fatigue (20%). GP “gut feeling” or clinical suspicion based on experience was a feature of 33% of referrals overall but with variation between the sites. Of 1,623 patients referred to the MDCs by February 2018, 142 cancers had been diagnosed (overall rate of 9%; range 4%–15%).

Although the evaluation continues, NHSE has incorporated the model into its future plans and proposes to “By

In keeping with this approach, NHSE is working with the ACE2 and cancer alliances to produce a national timed clinical pathway with accompanying resource pack which will act as a guide to the referral criteria, investigations, pathways, and data collection requirements for the new centers.

Clarity about the primary care epidemiology of symptoms possibly related to cancer as they are present in patients seeking medical help can help to provide a rational basis for planning diagnostic approaches. When it comes to planning services and arranging services cost-effectively, however there is more work to do. Many of the facilities and much of the expertise needed are common across the pathways, so it might make sense to co-locate dedicated diagnostic equipment and clinical staff in one place, and if so what might be the optimum population coverage of such a service?

Under this scenario how would cancer pathways requiring very specific equipment such as mammography fit? What might be the best model of clinical leadership? What size of service would be needed to have a significant impact at a whole population level?

The ACE2 pilots and the Danish experience give some insights on these issues, but there is scope to go beyond the current approaches and test out at a much larger scale what might be achievable by bringing together local provider resources into a collaborative diagnostic hub. An individual hospital may struggle to provide a rapid timely diagnostic service, not least because of workforce restraints, but it is possible that the MDC model will offer a solution by enabling standardized and rapid reporting of imaging, shared facilities, robust safety netting for test results and a “pooled” workforce.

**A new standard for faster diagnosis**

Efforts to make cancer diagnosis faster once patients have entered the health care system have received much attention in the NHS. These largely focus on reducing waiting after referral by setting a target for the overall time from referral to treatment of a maximum of 62 days and a number of subsidiary targets such as the 14-day maximum for referral to assessment.

There is a passionate debate in England as to the overall value of such targets and their clinical basis. For some types of cancer, faster diagnosis is crucially important. The UKLCC slogan “Millimetres Matter” reminds us that for lung cancer small delays in treatment significantly affect prognosis. For other cancer types, the impact on survival of achieving faster diagnosis may be less. Cancer waiting time measures are, however, perceived as a barometer of the effectiveness of the local cancer system both from a political standpoint and also by the public and media.

The national cancer task force recommended introduction of a new standard for faster diagnosis under which patients would be told whether they have cancer or not within 28 days of referral. When fully implemented in 2020 this Faster Diagnosis Standard (FDS) will replace the current 14-day maximum waiting time from referral to assessment. It is argued that the wait from referral to diagnosis (or confirmation that they do not have cancer) is more meaningful for patients.

NHSE has undertaken five pilots of the FDS to develop and test methods for measuring achievement of the standard, the definitions to be used, the additional capacity requirements for different cancer types, and the overall feasibility of introducing this measure. The pilot sites covered gynecology, urology, head and neck, lung, lower and upper GI cancer pathways. Based on the evidence from the pilot sites and in preparation for the new standard, an updated national Cancer Waiting Times information system was introduced from April 2018. Data collection for all patients will be in place in 2019 with the system being used to monitor FDS from April 2020.

**Timed diagnostic pathways (TDPs)**

The FDS pilot programs confirmed that the new standard will require radical rethinking of how cancer pathways work in many parts of England. To enable this, clinical leaders across the three parts of the NCV (Greater Manchester Cancer, Royal Marsden Partners, and the University College London Hospitals Cancer Collaborative) came together with NHSE’s Clinical Expert Groups to develop a series of TDPs. These show how timely and effective cancer diagnosis and care can be provided within the specified timescales. The pathways have also been shaped and endorsed by NHS England’s Clinical Steering Group and complement existing resources such as NICE Guidelines (including NG12) and crucially have involved patients at all stages.

The first three published TDPs cover colorectal, lung, and prostate cancers, and their implementation has been made mandatory for CCGs by NHSE. A further pathway for esophago-gastric cancer is in preparation. Each pathway and supporting handbook sets out how diagnosis within 28 days can be achieved by innovative approaches to the sequencing of tests, senior clinical oversight of the system, and limiting
the need for more invasive tests to those who will benefit most. Typically the pathways encourage streamlined, more rapid diagnostics and a treatment-focused multidisciplinary team meeting by day 21 after GP referral.

The resources published alongside each handbook support cancer alliances with implementation, and with the large-scale transformation across required whole systems. TDPs provide standardized pathways which are easier to benchmark, audit, and improve. They provide evidence-based guidance with which to help deliver the FDS and 62-day standard, improve patient experience, reduce unnecessary appointments and tests, and lead to a reduction in the marked unwarranted variation in cancer care across the country.

The clinical leaders involved in developing the pathways have identified a generic good practice checklist for managing cancer pathways within the NHS:69–71

- Daily senior triage of referrals to ensure appropriate investigations
- Straight to test and one-stop clinics to reduce unnecessary clinic attendances
- Reporting of scans immediately or within 24 hours
- Diagnostic “bundles” to reduce time taken by sequential testing
- Pathway navigators to ensure good communication and coordination
- Clear agreed protocols to avoid unnecessary consultations
- Avoid repeated MDTs to avoid delays and indecision

Examples of the innovations introduced by the nationally mandated TDPs include:

- Replacement of the traditional outpatient model for colorectal cancer with a straight to test approach based on a triage system undertaken by either a senior nurse or a doctor.69
- Consistent introduction of multi-parametric Magnetic Resonance Imaging early in prostate cancer diagnosis, thereby reducing prostate biopsies by up to 27%.71
- Reinforcing the concept of “straight to CT” for patients with abnormal chest X-rays in lung cancer diagnosis, thereby speeding up access to potentially curative treatment.70

These clinically led national initiatives are leading to improvements in patients as they are introduced locally by cancer alliances with the impact being seen in national data. Early unpublished evidence following the introduction of the TDPs shows rapid improvements with for example achievement of the 62-day treatment standard improving from 44% to 78% for prostate cancer, 58% to 84% for colorectal cancer, and 62% to 75% for lung cancer.71

Our experience of producing the TDPs shows that with the right clinical leadership and commitment, sufficient clinical consensus to take action can be achieved in a short time frame. This work has been positively received with the high level of clinical buy in enabling the incorporation of the pathways into national commissioning guidance.72 Future work will expand the scope of the pathways to include primary care elements, treatment pathways, and ongoing care.

**Cancer alliances, the cancer vanguard, and the role of clinicians**

In line with the National Cancer Taskforce recommendations, 19 cancer alliances were created across England from 2016 to provide coordination and leadership of cancer care for populations of up to 6.3 million. They were tasked by NHS England72 with:

- Ensuring collaborative working across their locality
- Aligning with Sustainability and Transformation Partnerships (STPs)
- Focusing on place-based approaches to improve cancer outcomes
- Implementing the recommendations of the National Cancer Taskforce
- Using additional transformation funding to achieve earlier and faster cancer diagnosis
- Rolling out personalized care and support for people during and after their cancer treatment

Three of the alliances (Greater Manchester, North Central and North East London, and North West and South West London collectively covering 10.7 million people or 18% of England’s population) were initially designated together (between 2015 and 2018) as the NCV with the additional task of developing new models of care and tools for measuring cancer outcomes that could be applied consistently across the country.73 A key feature of alliances was the inclusion of people affected by cancer in their governance and work programs, along with the extensive stakeholder involvement. These wider perspectives gave more legitimacy and energy to the projects undertaken.

Cancer alliances operate in a complex NHS environment with a mixture of statutory bodies such as NHS Trusts, NHS Foundation Trusts, and CCGs with non-statutory arrangements such as Sustainability and Transformation Plans and a variety of new models of inter-provider cooperation such as the “group” model exemplified by The Northern Care...
Cancer alliances are seen by NHSE as providing “cancer-specific leadership for the new Sustainability and Transformation Plan (STP) footprints”. The King’s Fund has described STPs as a “conscious workaround” of the fragmented health system created by the Health and Social Care Act 2012. The Health Service Governance Handbook suggests they are grappling with such basic governance questions such as accountability, patient and public engagement, relationships with local government, balancing rapid with transparent decision-making, clinical engagement, the role of lay members and non-executives, and audit and assurance processes. It is not surprising that these issues also remain a challenge for cancer alliances despite the guidance from NHSE.

Cancer alliances and similar models also pose challenges for regulators in working out how to place service contracts, work with partnerships rather than individual organizations, allocate funding, share risk and rewards, and measure and rate performance. One objective of the cancer vanguard was to explore these issues but while much progress has been made in improving cancer commissioning as recommended by the independent cancer task force particularly through the establishment of alliances, the specific recommendation that “the entire cancer pathway in at least one area should have a fully devolved budget over multiple years, based on achieving a pre-specified set of outcomes” has been proven problematic. The reasons for this are being evaluated, but lessons learned will be useful in future attempts to align the success of cancer alliance clinical pathway boards in designing new streamlined pathways of care with financial and commissioning incentives. Cancer commissioning systems in England remain fragmented and variably effective, and this must be addressed if, for example, the increase in deaths from breast cancer projected in an analysis by Breast Cancer Now is to be averted.

At system level, the link between research, innovation, education, and high-quality care and outcomes is enshrined in the construct of the comprehensive cancer center (CCC) or system which finds slightly different manifestations in the USA and Europe. Within the CCC, the concept of “team science” in which scientists and clinicians work together to create clinically meaningful questions and produce implementable solutions can flourish. The challenge is then to spread the innovation beyond the immediate reach of the CCC to ensure consistent and equitable nationwide implementation.

Our experience is that the combination of a CCC providing a distributed service network with a strong cancer alliance securely tied into the overall health governance system of a...
region is a powerful driver for on the ground implementation of the national cancer plan, rapid adoption of innovation, and equitable access to care across a large population.

Our proposition is that the leadership of cancer alliances in England could beneficially be accompanied by stronger and more consistent networking of the operational service delivery system. This should be reinforced by refocusing of the commissioning and regulatory regimes, so that they actively support clinical pathways and ensure focus on the prevention, early detection and faster diagnosis of cancer that will enable the new treatments at our disposal to have the greatest possible effect.

Conclusion
National and local initiatives described in this review are addressing the apparent stoicism and behavioral reserve that may be delaying English patients consulting GPs and are building clearer evidence-based pathways and capacity to enable GPs to refer or investigate appropriately at an earlier stage. Nationally mandated diagnostic pathways are being implemented which are having early success in driving the changes needed to diagnose or rule out cancer within 28 days of referral. The application of the concept of the MDC in England is being actively explored with some alliances prepared to take a bolder approach and test the concept at a much larger scale than has until now been attempted.

Clinically led initiatives and a strong patient voice coordinated by cancer alliances have been shown to be capable of reforming care for patients and are a cause for optimism. As cancer alliances mature, we anticipate that they will benefit from further innovative approaches to provider collaboration with networks based on the CCC model being our preferred approach to ensuring dissemination of good practice. At the same time, ensuring greater alignment of regulators and less fragmentation of commissioners to enable them to concentrate on what really matters should be a national priority.

Disclosure
The authors report no conflicts of interest in this work.

References


